Medibank Private Limited

Group operating profit increased 6% to $381.7 million, and underlying EPS was $0.108 per share, in line with last year. Health insurance delivered 4.3% revenue growth and 4.4% gross profit growth, with gross margin stable at 16.2%; operating profit rose 3.5% to $361.5 million and operating margin remained 8.5%. Resident policyholder numbers increased 1.9% over 12 months, including 0.9% growth in the last 6 months. Medibank Health segment profit increased 28.5% to $48.3 million on 27.5% revenue growth. The interim dividend was $0.083 per share, 6.4% higher, and capital stood at 1.9x PCA with a 13.8% capital ratio. For FY '26, management left resident and nonresident outlooks unchanged, expects resident claims growth per policy unit of 2.6% to 2.9%, and expects Medibank Health organic operating profit growth to be similar to 1H '26 plus about $6 million from Better Medical in 2H.

David Koczkar framed the half as evidence that Medibank is gaining traction in both insurance and health services, with customer engagement improving and the health-transition strategy accelerating. He emphasized that more customers are using Medibank Health offerings, primary care is expanding through Myhealth and Better Medical, and AI adoption is speeding up across the business. His tone was confident but measured, with repeated focus on affordability, system reform, and disciplined growth rather than volume at any cost.

Mark Rogers highlighted balanced growth and margin discipline, noting operating profit of $381.7 million, stable resident gross margin of 15.5%, and health insurance expense growth of 5.4% to $329.4 million. He said FY '26 expenses are expected to be between $690 million and $695 million, including $10 million of productivity savings, and cyber costs should be around $35 million. He also noted capital is strong, the Better Medical deal used $163.5 million of capital, and the company still has capacity for further inorganic growth while keeping the interim dividend at $0.083 per share.

Analysts focused on claims inflation, revenue mix/downgrading, hospital inflation, and whether the 5.1% premium increase signals higher future claims. Management said the gap between premium growth and cash claims is mainly revenue mix, cited a COVID-related tailwind and New South Wales private room costs, and said flat jaws in 2H is a plausible outcome. Questions also probed aggregators, nonresident weakness, and capital deployment; management said aggregator pressure is mostly on ahm, student lapses were tied to graduation after prior COVID-era intake, and future capital is likely to go first into primary care, with broader options including well-being or even industry consolidation longer term.